Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.
about
Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland BioreactorFcRn overexpression in transgenic mice results in augmented APC activity and robust immune response with increased diversity of induced antibodiesCharacterization of the rabbit neonatal Fc receptor (FcRn) and analyzing the immunophenotype of the transgenic rabbits that overexpresses FcRnTargeting FcRn for therapy: from live cell imaging to in vivo studies in mice.IgG subclasses and allotypes: from structure to effector functions.Regulation of immune responses by the neonatal fc receptor and its therapeutic implicationsCharacterization and screening of IgG binding to the neonatal Fc receptor.Overexpression of Bovine FcRn in Mice Enhances T-Dependent Immune Responses by Amplifying T Helper Cell Frequency and Germinal Center Enlargement in the Spleen.A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.NFκB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn.On the emerging role of rabbit as human disease model and the instrumental role of novel transgenic tools.Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity.Linkage haplotype for allotypic variants of porcine IgA and IgG subclass genes.
P2860
Q26745000-77E9D83D-9550-4503-8CCF-0F63D3B774A6Q28730212-920D32B5-DE56-4847-A1F9-6F4633F98251Q28732874-B0D7192A-0EDC-4D17-9DED-EEE94461EFC9Q33758483-1A8B90F6-82A7-4C45-B8B1-1A0403DADFA6Q34368678-A3D2B284-5CBC-49C5-B11D-9D99D1BC6B94Q34818194-9AC33CD9-6E48-4F1A-A685-4B79B6627CCEQ35163945-663993C9-77CE-48AD-82BD-417DB82F9A78Q35866344-1266DD7B-2998-4BF1-96DA-86E1DBFE59CCQ36211427-F7BF6392-E0E5-421F-9188-DFD13C4929E7Q37496557-D38070F6-7256-43AD-B262-E737DFBB9586Q37989800-FE271A59-1622-412E-B4AE-053C63995156Q37998314-F24DFC1B-E0CA-4C40-996F-2A1614EC0343Q38176932-0F70FE8F-6FB6-4E31-8A6C-A89F478632E2Q38615389-23CFC953-58C7-4EAC-A078-8D06CF00DB18Q48639424-1BCF727D-6481-4DE6-BACF-59A62D6A58D5
P2860
Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Recent advances using FcRn ove ...... ration of specific antibodies.
@ast
Recent advances using FcRn ove ...... ration of specific antibodies.
@en
type
label
Recent advances using FcRn ove ...... ration of specific antibodies.
@ast
Recent advances using FcRn ove ...... ration of specific antibodies.
@en
prefLabel
Recent advances using FcRn ove ...... ration of specific antibodies.
@ast
Recent advances using FcRn ove ...... ration of specific antibodies.
@en
P2093
P2860
P356
P1476
Recent advances using FcRn ove ...... eration of specific antibodies
@en
P2093
John E Butler
Judit Cervenak
Richard A Goldsby
P2860
P304
P356
10.4161/MABS.3.5.17023
P577
2011-09-01T00:00:00Z